Pluripotent stem cell for treatment of chronic kidney disease

Abstract

An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating chronic kidney disease that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a renal tissue regeneration mechanism by which Muse cells are made to selectively accumulate at a site of kidney disease and differentiate into cells that compose the kidney by administering Muse cells intravenously to a subject having the aforementioned disease.

1 . A cell preparation for preventing and/or treating chronic kidney disease, containing pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. 
     
     
         2 . The cell preparation according to  claim 1 , wherein the pluripotent stem cells positive for SSEA-3 contain a concentrated cell fraction as a result of stimulation by external stress. 
     
     
         3 . The cell preparation according to  claim 1 , wherein the chronic kidney disease is selected from the group consisting of chronic glomerular nephritis, renal sclerosis, diabetic nephropathy, renal cyst, chronic pyelonephritis, rapidly progressive glomerulonephritis, malignant hypertension, SLE nephritis, renal amyloidosis, renal/urinary tract tumors, myeloma, obstructive uropathy, renal gout, renal hypoplasia and renal/urinary tract tuberculosis. 
     
     
         4 . The cell preparation according to  claim 1 , wherein the pluripotent stem cells are CD105-positive. 
     
     
         5 . The cell preparation according to  claim 1 , wherein the pluripotent stem cells are CD117-negative and CD146-negative. 
     
     
         6 . The cell preparation according to  claim 1 , wherein the pluripotent stem cells are CD117-negative, CD146-negative, NG2-negative, CD34-negative, vWF-negative and CD271-negative. 
     
     
         7 . The cell preparation according to  claim 1 , wherein the pluripotent stem cells are CD34-negative, CD117-negative, CD146-negative, CD271-negative, NG2-negative, vWF-negative, Sox10-negative, Snail-negative, Slug-negative, Tyrp1-negative and Dct-negative. 
     
     
         8 . The cell preparation according to  claim 1 , wherein the pluripotent stem cells are pluripotent stem cells having all of the properties indicated below:
 (i) low or absent telomerase activity;   (ii) ability to differentiate into any of the three germ layers;   (iii) absence of demonstration of neoplastic proliferation; and,   (iv) self-renewal ability.   
     
     
         9 . The cell preparation according to  claim 1 , wherein the pluripotent stem cells have the ability to accumulate at the site of kidney disease. 
     
     
         10 . The cell preparation according to  claim 1 , wherein the pluripotent stem cells have the ability to differentiate into one or more cells selected from the group consisting of foot cells, mesangium cells, glomerular endothelial cells, juxtaglomerular cell, proximal tubular cells, distal tubular cells, vascular endothelial cells, Henle's loop, and/or collecting tubule cells.